NovaQuest Capital Management, a healthcare and life sciences focused private investment firm, has held the final close of NovaQuest Private Equity Fund I (Fund I) with USD275 million in total capital commitments.
Fund I will continue NovaQuest’s focus on investing in and building leading services and technologies in the healthcare and life sciences sector with a dedicated private equity platform.
Fund I was oversubscribed, hitting its hard cap of USD275 million through strong support from a global investor base including leading insurance companies, pension funds, asset managers, fund of funds, family offices and high net worth individuals.
“We thank our investors for the partnership and confidence they have placed in us and are excited to capitalise on the attractive investment opportunities and value-creation capabilities NovaQuest brings to the market,” says the leadership team of NovaQuest Private Equity.
Fund I started investing in March 2018 and has made three platform investments and two add-on acquisitions to date: Azurity Pharmaceuticals, a leading provider of drug delivery technology solutions that provide patients access to customised dosage forms; Clinical Ink, a provider of eClinical services and technologies, including eSource, ePRO, eCOA, among others; and Catalyst Clinical Research, a provider of outsourced clinical services for clinical trials.
NovaQuest Private Equity targets growth-oriented opportunities that help reduce the total cost of care, meet unmet medical needs, reduce unnecessary procedures, improve efficacy (therapeutics or prevention) and / or improve the quality of life. With a dedicated private equity effort, NovaQuest can continue to partner with top tier management teams, providing them with strategic capital and best in-class operational resources. NovaQuest’s strategic partners, Operating Advisory Board, and deep industry network differentiates the Firm with powerful value creation capabilities for middle market healthcare companies.
The partners of NovaQuest Private Equity say: “We are grateful for all the support we have received in achieving this great milestone to create a differentiated specialists investor in the healthcare and life sciences sector and in successfully raising our first dedicated private equity fund. From the beginning the Firm’s founders, Dennis Gillings, PhD, CBE and Ron Wooten, shared a vision with our team and they laid the foundation for the Fund’s creation with their invaluable support through their cornerstone, healthcare expertise and extensive networks. Dr Gillings, Ron, and our team have been joined by our industry advisors and the institutions who have invested in the Fund.”
Eaton Partners, one of the world’s leading private capital advisory and fund placement firms and a wholly owned subsidiary of Stifel Financial Corp (SF), acted as exclusive placement agent and fundraising advisor.
